Latest market price
4.11
-0.20-4.64%
TA
Loading chart...
Snapshot
| Index | — | P/E | — | EPS (ttm) | -2.08 | Insider Own | 30.21% | Shs Outstand | 80.20M | Perf Week | 1.73% |
| Market Cap | 329.64M | Forward P/E | — | EPS next Y | -1.48 | Insider Trans | 0.03% | Shs Float | 60.34M | Perf Month | -19.41% |
| Enterprise Value | 110.64M | PEG | — | EPS next Q | -0.51 | Short Float | 5.09% | Perf Quarter | -10.85% | ||
| Income | -165.00M | P/S | — | EPS this Y | — | Short Ratio | 10.15 | Perf Half Y | -26.34% | ||
| Sales | 0.00 | P/B | 1.62 | EPS next Y | — | ROA | -71.16% | Short Interest | 3.07M | Perf YTD | 15.13% |
| Book/sh | 2.54 | P/C | 1.51 | EPS next 5Y | — | ROE | -64.25% | 52W High | 6.45 -36.28% | Perf Year | 24.92% |
| Cash/sh | 2.73 | P/FCF | — | EPS past 3/5Y | — | ROIC | -86.35% | 52W Low | 2.87 43.21% | Perf 3Y | 38.85% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | — | Gross Margin | 0.00% | Volatility | 5.55% 5.16% | Perf 5Y | -67.71% |
| Dividend TTM | — | EV/Sales | — | EPS Y/Y TTM | — | Oper. Margin | 0.00% | ATR (14) | 0.24 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 8.13 | Sales Y/Y TTM | — | Profit Margin | 0.00% | RSI (14) | 32.39 | Recom | 3.00 |
| Dividend Gr. 3/5Y | — | Current Ratio | 8.13 | EPS Q/Q | 6.82% | SMA20 | -9.73% | Beta | 0.76 | Target Price | 7.00 |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | — | SMA50 | -18.51% | Rel Volume | 1.24 | Prev Close | 4.31 |
| Employees | 55 | LT Debt/Eq | 0.00 | Earnings | Nov 11 | SMA200 | -16.61% | Avg Volume | 281.15K | Price | 4.11 |
| IPO Date | Oct 30, 2020 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 26.13% — | Net Debt/EBITDA | — | Volume | 349,862 | Change | -4.64% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-13-26 | Reiterated | Morgan Stanley | Equal Weight | $6.88 → $7.00 |
| Mar-09-26 | Reiterated | Evercore ISI Group | Outperform | $10 |
| Aug-13-24 | Upgrade | Morgan Stanley | Underweight → Equal Weight | $6.88 |
| Aug-10-23 | Downgrade | JP Morgan | Neutral → Underweight | |
| Jan-06-22 | Downgrade | Morgan Stanley | Equal Weight → Underweight | |
| Nov-18-21 | Downgrade | SVB Leerink | Outperform → Market Perform | |
| Oct-20-21 | Downgrade | JP Morgan | Overweight → Neutral | |
| Oct-05-21 | Downgrade | Morgan Stanley | Overweight → Equal Weight |
Latest News· Times ET
Sep-15-26
Sep-15-2604:41PM
Sep-08-26
Sep-08-2607:00AM
Sep-02-26
Sep-02-2604:24AM
Aug-19-26
Aug-13-26
Aug-13-2606:15AM
Aug-12-26
06:05PM
Atea Pharmaceuticals Q2 Earnings Call Highlightsmarketbeat.com
04:05PM
Aug-05-26
Aug-05-2607:00AM
Jul-28-26
Jul-28-2607:00AM
Jul-14-26
Jul-14-2607:00AM
Jul-10-26
Company
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 38 | 0 | 83 | 70 | — | — | — | — | — | |
| Gross Profit | -38 | 0 | -83 | -70 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 28 | 33 | 49 | 50 | — | — | — | — | — | |
| Research and Development | 155 | 148 | 145 | 133 | — | — | — | — | — | |
| Other Operating Expense | -38 | 0 | -84 | -89 | — | — | — | — | — | |
| Operating Income | -184 | -181 | -193 | -164 | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 12 | 16 | 25 | 29 | — | — | — | — | — | |
| Net Income Before Taxes | -172 | -165 | -167 | -135 | — | — | — | — | — | |
| Income Taxes | -7 | -6 | 1 | 1 | — | — | — | — | — | |
| Consolidated Net Income | -165 | -158 | -168 | -136 | — | — | — | — | — | |
| Net Income From Continuing Operations | -165 | -158 | -168 | -136 | — | — | — | — | — | |
| Net Income | -165 | -158 | -168 | -136 | — | — | — | — | — | |
| EPS (Recurring) | -2.08 | -1.94 | -2.00 | -1.63 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -2.08 | -1.94 | -2.00 | -1.63 | — | — | — | — | — | |
| EPS (Diluted) | -2.08 | -1.94 | -2.00 | -1.63 | — | — | — | — | — | |
| EBITDA | -172 | -164 | -132 | -120 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | |
| Shares Outstanding | 80 | 81 | 84 | 83 | — | — | — | — | — | |
| Market Capitalization | 329 | 289 | 281 | 253 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| BERGER FRANKLIN M | Director | Jun 18 '26 | Option Exercise | 0.00 | 29,600 | 0 | 536,097 | Jun 23 |
| DUNCAN BARBARA GAYLE | Director | Jun 18 '26 | Option Exercise | 0.00 | 29,600 | 0 | 92,350 | Jun 23 |
| Lucidi Bruno | Director | Jun 18 '26 | Option Exercise | 0.00 | 29,600 | 0 | 142,350 | Jun 23 |
| Polsky Bruce | Director | Jun 18 '26 | Option Exercise | 0.00 | 29,600 | 0 | 124,806 | Jun 23 |
| Murphy Polly A. | Director | Jun 18 '26 | Option Exercise | 0.00 | 29,600 | 0 | 121,745 | Jun 23 |
| Adams Jerome M. | Director | Jun 18 '26 | Option Exercise | 0.00 | 29,600 | 0 | 92,350 | Jun 23 |
| Murphy Polly A. | Director | May 18 '26 | Buy | 4.17 | 6,100 | 25,446 | 92,145 | May 21 |
| Murphy Polly A. | Director | May 18 '25 | Buy | 4.17 | 6,100 | 25,446 | 92,145 | May 20 |
| Corcoran Andrea | Officer | Mar 11 '26 | Option Exercise | 1.24 | 120,000 | 148,800 | 823,576 | Mar 13 |
| Sommadossi Jean-Pierre | President, CEO, and Chairman | Feb 03 '26 | Option Exercise | 1.24 | 300,000 | 372,000 | 767,830 | Feb 03 |
| Horga Maria Arantxa | Chief Medical Officer | Jan 31 '26 | Option Exercise | 0.00 | 61,033 | 0 | 112,159 | Feb 03 |
| Vavricka John | Chief Commercial Officer | Jan 31 '26 | Option Exercise | 0.00 | 50,833 | 0 | 94,164 | Feb 03 |
| Hammond Janet MJ | Chief Development Officer | Jan 31 '26 | Option Exercise | 0.00 | 69,300 | 0 | 141,801 | Feb 03 |
| Corcoran Andrea | Officer | Jan 31 '26 | Option Exercise | 0.00 | 65,366 | 0 | 779,680 | Feb 03 |
| Sommadossi Jean-Pierre | President, CEO, and Chairman | Jan 31 '26 | Option Exercise | 0.00 | 372,500 | 0 | 573,923 | Feb 03 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.